Further understanding of recombinant activated factor VII mode of action.

Abstract:

:Recombinant activated factor VII (rFVIIa) is being increasingly used to treat bleeding associated with a variety of non-hemophilic coagulopathic indications, and its mechanism of action in these areas is under active investigation. Numerous studies have shown that FVIIa binds with low affinity to activated platelets; rFVIIa can subsequently enhance platelet-surface thrombin generation by activating factor (F) X and by contributing additional FIXa to the hemostatic process. This FIXa can rapidly activate additional FX, which may explain why non-hemophilic coagulopathic bleeds respond to lower doses of rFVIIa than do hemophilic bleeds. However, the platelet surface may be able to process only a limited amount of FXa, accounting for the observation that some models of non-hemophilic coagulopathy show a plateau in the effect of rFVIIa.

journal_name

Semin Hematol

journal_title

Seminars in hematology

authors

Monroe DM

doi

10.1053/j.seminhematol.2008.03.013

subject

Has Abstract

pub_date

2008-04-01 00:00:00

pages

S7-S11

issue

2 Suppl 1

eissn

0037-1963

issn

1532-8686

pii

S0037-1963(08)00053-X

journal_volume

45

pub_type

杂志文章,评审
  • Pharmacokinetics of all-trans-retinoic acid: clinical implications in acute promyelocytic leukemia.

    abstract::Continuous daily treatment with all-trans-retinoic acid (ATRA) in patients with acute promyelocytic leukemia has been associated with a marked decline in the plasma drug concentration at the time of relapse. Recent pharmacologic studies have attempted to determine the reasons for the progressive reduction of plasma co...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:

    authors: Adamson PC

    更新日期:1994-10-01 00:00:00

  • Surgery in hemophilia. The general view: patient selection, timing, and preoperative assessment.

    abstract::Although often overlooked, the life of the patient with severe hemophilia is characterized by both intermittent and chronic pain. Bleeds into joints and muscles cause extensive pressure on sensory nerves and, following recurrent bleeds, joint destruction, and synovial reaction is accompanied by constant pains that are...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminhematol.2005.11.024

    authors: Ingerslev J,Hvid I

    更新日期:2006-01-01 00:00:00

  • Interactions of platelets and endothelial cells with erythrocytes and leukocytes in thrombotic thrombocytopenic purpura.

    abstract::In both normal and abnormal vascular biology, platelet-leukocyte-RBC-EC adhesive and functional interactions appear to play a significant role. The clinical hallmarks of the TTP/HUS syndromes, including prominent platelet aggregation and thrombi without prominent soluble coagulation system activation along with microa...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:

    authors: Smith BR,Rinder HM

    更新日期:1997-04-01 00:00:00

  • Mantle-cell lymphoma.

    abstract::Mantle-cell lymphoma (MCL) is a lymphoproliferative disorder derived from a subset of naive pregerminal center cells characterized by a nodular or diffuse proliferation of atypical lymphoid cells with a monoclonal B-cell phenotype and coexpression of CD5. Two cytologic variants have been identified, typical and blasti...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:

    authors: Campo E,Raffeld M,Jaffe ES

    更新日期:1999-04-01 00:00:00

  • Reducing mortality associated with immediate treatment complications of adult leukemias.

    abstract::Analysis of data from 806 patients with newly diagnosed adult acute myelocytic leukemia (AML) (not including acute promyelocytic leukemia [APL] patients) treated at M.D. Anderson Cancer Center from 1995 through 1999 indicated that among patients entering a particular week of induction therapy, mortality rates were 6%,...

    journal_title:Seminars in hematology

    pub_type: 杂志文章

    doi:10.1016/s0037-1963(01)90042-3

    authors: Estey E

    更新日期:2001-10-01 00:00:00

  • Hydroxyurea therapy for diverse pediatric populations with sickle cell disease.

    abstract::Hydroxyurea (HU) is the first widely used treatment to have an impact on the severity of disease in adult patients with sickle cell anemia, but limited data are available for younger patients or those with variant genotypes. We reviewed 324 months of experience with HU in 16 patients from 5.3 to 18.4 years of age trea...

    journal_title:Seminars in hematology

    pub_type: 临床试验,杂志文章

    doi:

    authors: Rogers ZR

    更新日期:1997-07-01 00:00:00

  • Mouse models in bone marrow transplantation and adoptive cellular therapy.

    abstract::Mouse models of transplantation have been indispensable to the development of bone marrow transplantation (BMT). Their role in the generation of basic science knowledge is invaluable and is subject to discussion below. However, this article focuses on the direct role and relevance of mouse models towards the clinical ...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminhematol.2013.03.026

    authors: Arber C,Brenner MK,Reddy P

    更新日期:2013-04-01 00:00:00

  • Targeted therapies in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia.

    abstract::Imatinib mesylate (Gleevec, Novartis Pharmaceuticals Corp, East Hanover, NJ; Glivec, Novartis Pharma AG, Basel, Switzerland), a signal transduction inhibitor with preferential effects against the tyrosine kinase activity of the protein product of the ABL proto-oncogene, induced hematologic responses in >or=90% of pati...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/shem.2002.36927

    authors: Hoelzer D,Gökbuget N,Ottmann OG

    更新日期:2002-10-01 00:00:00

  • Novel agents in the treatment of Hodgkin lymphoma: Biological basis and clinical results.

    abstract::Hodgkin Lymphoma (HL) is a lymphoproliferative disorder of B cells that commonly has a favorable prognosis when treated with either combination chemotherapy and radiation therapy, or chemotherapy alone. However, the prognosis for patients who relapse, or have evidence for refractory disease, is poor and new treatments...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminhematol.2016.05.011

    authors: Younes A,Ansell SM

    更新日期:2016-07-01 00:00:00

  • Non-Diamond Blackfan anemia disorders of ribosome function: Shwachman Diamond syndrome and 5q- syndrome.

    abstract::A number of human disorders, dubbed ribosomopathies, are linked to impaired ribosome biogenesis or function. These include but are not limited to Diamond Blackfan anemia (DBA), Shwachman Diamond syndrome (SDS), and the 5q- myelodysplastic syndrome (MDS). This review focuses on the latter two non-DBA disorders of ribos...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminhematol.2011.01.002

    authors: Burwick N,Shimamura A,Liu JM

    更新日期:2011-04-01 00:00:00

  • Molecular evaluation of acute myeloid leukemias.

    abstract::Traditionally, acute myeloid leukemia (AML) has been diagnosed and classified based on the morphologic and cytochemical criteria of the French-American-British (FAB) classification system. However, more recent studies have demonstrated that the cytogenetic and molecular genetic abnormalities consistently associated wi...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:

    authors: Willman CL

    更新日期:1999-10-01 00:00:00

  • ZAP-70 and defects of T-cell receptor signaling.

    abstract::The activation, function, and development of peripheral T lymphocytes are dependent on the ability to signal properly through the surface T-cell antigen receptor (TCR)-CD3 complex. Transmission of such signals requires the activation of specific cytoplasmic protein tyrosine kinases (PTK) associated with the TCR. Recen...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:

    authors: Elder ME

    更新日期:1998-10-01 00:00:00

  • High-dose therapy with hematopoietic transplantation for Hodgkin's lymphoma.

    abstract::The use of combination chemotherapy has been successful in treating advanced or widespread Hodgkin's disease (HD). For patients with relapsed disease, the long-term prognosis is much poorer, despite the good rate of reinduction into a second or further remission using conventional treatments. The majority of such pati...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:

    authors: Laurence AD,Goldstone AH

    更新日期:1999-07-01 00:00:00

  • Nonablative stem cell transplantation for older patients with acute leukemias and myelodysplastic syndromes.

    abstract::High-dose chemoradiotherapy with allogeneic bone marrow or peripheral blood stem cell transplantation (SCT) is a potentially curative treatment for advanced or poor-prognosis hematological malignancies. This procedure was initially considered as a means to deliver supralethal doses of chemotherapy and radiation for th...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/shem.2002.30909

    authors: Giralt S,Anagnostopoulos A,Shahjahan M,Champlin R

    更新日期:2002-01-01 00:00:00

  • Transplant decision-making strategies in the myeloproliferative disorders.

    abstract::Myelofibrosis with myeloid metaplasia, also known as idiopathic myelofibrosis (IF) or agnogenic myeloid metaplasia, is one of the characteristic manifestations of polycythemia vera (PV) in the spent phase, and has a particularly adverse prognosis. IF may also present de novo. To date, treatment strategies for both spe...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/shem.2003.50032

    authors: Fruchtman SM

    更新日期:2003-01-01 00:00:00

  • The manufacturing process for recombinant factor IX.

    abstract::Advances in recombinant DNA manufacturing technology have now made possible the production of a highly purified and active recombinant factor IX (rFIX) product. Recombinant factor IX was developed by (1) stable insertion of the genes for both factor IX and PACE-SOL (a truncated, soluble serine protease needed to enhan...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:

    authors: Harrison S,Adamson S,Bonam D,Brodeur S,Charlebois T,Clancy B,Costigan R,Drapeau D,Hamilton M,Hanley K,Kelley B,Knight A,Leonard M,McCarthy M,Oakes P,Sterl K,Switzer M,Walsh R,Foster W

    更新日期:1998-04-01 00:00:00

  • A clinical review of bleeding dilemmas in trauma.

    abstract::Trauma is rapidly replacing stroke and cardiovascular disease as a leading cause of death in Western countries such as the United States, and almost a third (30%) of trauma deaths are due to blood loss. Although the new intervention strategies that have been developed and adopted by emergency care staff have reduced t...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminhematol.2003.11.009

    authors: Hoyt DB

    更新日期:2004-01-01 00:00:00

  • Novel agents in development for peripheral T-cell lymphoma.

    abstract::Though peripheral T-cell lymphoma (PTCL) is an area of significant unmet therapeutic need, a number of new treatment options are available for patients, especially those with relapsed or refractory disease. A plethora of drugs are now in development for PTCL, but drugs that truly target novel disease biology are notic...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminhematol.2010.01.014

    authors: O'Connor OA

    更新日期:2010-04-01 00:00:00

  • Advances in the treatment of von Willebrand disease.

    abstract::Von Willebrand disease (VWD) is the most commonly inherited bleeding disorder, caused by inheritance of a quantitative or qualitative abnormality of von Willebrand factor (VWF). While the majority of patients with VWD are successfully treated with adjunctive therapies or with the synthetic vasopressin analog desmopres...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1016/s0037-1963(01)90131-3

    authors: Hambleton J

    更新日期:2001-10-01 00:00:00

  • Control of late neutrophil-specific gene expression: insights into regulation of myeloid differentiation.

    abstract::During myeloid differentiation, the pluripotent hematopoietic stem cell passes through several well-defined morphologic stages within the bone marrow. These changes include progressive nuclear segmentation and the acquisition of stage-specific granules. Primary granules appear at the myeloblast stage, and are found in...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:

    authors: Sigurdsson F,Khanna-Gupta A,Lawson N,Berliner N

    更新日期:1997-10-01 00:00:00

  • Pathogenetic mechanisms in chronic myeloproliferative disorders: polycythemia vera, essential thrombocythemia, agnogenic myeloid metaplasia, and chronic myelogenous leukemia.

    abstract::The stem cell origination of the clonal process in chronic myeloproliferative disorders (CMPDs) is well established. In chronic myelogenous leukemia (CML), the primary genetic process has been characterized. However, current information regarding the mechanisms of phenotypic diversity among the CMPD and the downstream...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:

    authors: Tefferi A

    更新日期:1999-01-01 00:00:00

  • Future strategies toward the cure of indolent B-cell malignancies. Immune recognition and antiself.

    abstract::Tumor cells from patients with B-cell malignancies exhibit a number of immunophenotypic characteristics that may be responsible for their survival. It has been shown, for example, that down-modulation of CD154 (CD40 ligand), which allows B cells to respond to T cells, may account for some of the immune defects of thes...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:

    authors: Nadler LM

    更新日期:1999-10-01 00:00:00

  • Mismatched unrelated donor transplantation.

    abstract::There are now more than 25 million volunteer donors registered worldwide for patients in need of a life-saving hematopoietic cell transplant to cure blood disorders. Although a human leukocyte antigen (HLA)-matched donor remains the preferred stem cell source for transplantation, the use of a donor with limited HLA mi...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminhematol.2016.07.003

    authors: Petersdorf EW

    更新日期:2016-10-01 00:00:00

  • Cellular hematopoiesis in the twentieth century.

    abstract::From work particularly In the last two decades of the century, the cell populations forming blood cells can now be purified and cultured clonally so that blood cell formation can be analyzed in vitro. A large number of specific regulators of this process have been identified and mass-produced in recombinant form. Thre...

    journal_title:Seminars in hematology

    pub_type: 历史文章,杂志文章,评审

    doi:

    authors: Metcalf D

    更新日期:1999-10-01 00:00:00

  • The effect of recombinant human colony-stimulating factors on hematopoietic reconstitution following autologous bone marrow transplantation.

    abstract::The prolonged and severe myelosuppression associated with high-dose chemotherapy and autologous bone marrow transplantation is a major causative factor in patient morbidity and mortality resulting from infection and other causes. The recent molecular cloning, in vitro expression, and formulation of recombinant human c...

    journal_title:Seminars in hematology

    pub_type: 杂志文章

    doi:

    authors: Peters WP

    更新日期:1989-04-01 00:00:00

  • New therapeutic strategies in acute lymphoblastic leukemia.

    abstract::While cure rates of over 80% are achieved in contemporary pediatric acute lymphoblastic leukemia (ALL) protocols, most adults with ALL succumb to their disease, and little progress has been made in the treatment of refractory and relapsed ALL. Moreover, the burden of therapy is high in a significant number of newly di...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminhematol.2008.09.009

    authors: Jeha S

    更新日期:2009-01-01 00:00:00

  • Improving CAR T-cells: The next generation.

    abstract::The introduction of chimeric antigen receptor (CAR) T-cell therapy in acute lymphoblastic leukemia (ALL) has dramatically altered the landscape of treatment options available to children and adults with ALL. With complete remission induction rates exceeding 70% in most trials and FDA approval of one CD19 CAR T-cell co...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1053/j.seminhematol.2020.07.002

    authors: Marple AH,Bonifant CL,Shah NN

    更新日期:2020-07-01 00:00:00

  • The Oklahoma Thrombotic Thrombocytopenic Purpura-Hemolytic Uremic Syndrome (TTP-HUS) Registry: a community perspective of patients with clinically diagnosed TTP-HUS.

    abstract::The Oklahoma Thrombotic Thrombocytopenic Purpura-Hemolytic Uremic Syndrome (TTP-HUS) Registry enrolls all consecutive patients for whom plasma exchange treatment is requested for clinically diagnosed TTP-HUS within a defined geographic region. During 14.5 years, from January 1, 1989 until June 30, 2003, 301 patients h...

    journal_title:Seminars in hematology

    pub_type: 杂志文章

    doi:10.1053/j.seminhematol.2003.10.001

    authors: George JN,Vesely SK,Terrell DR

    更新日期:2004-01-01 00:00:00

  • Structural and functional characterization of B-domain deleted recombinant factor VIII.

    abstract::A new high-purity recombinant factor VIII preparation has been developed for the treatment of hemophilia A. Structurally, this factor VIII preparation, B-domain deleted recombinant factor VIII (BDDrFVIII), differs from other recombinant and plasma-derived factor VIII preparations in that most of the B-domain has been ...

    journal_title:Seminars in hematology

    pub_type: 杂志文章,评审

    doi:10.1016/s0037-1963(01)90103-9

    authors: Sandberg H,Almstedt A,Brandt J,Castro VM,Gray E,Holmquist L,Lewin M,Oswaldsson U,Mikaelsson M,Jankowski MA,Bond M,Scoble HA

    更新日期:2001-04-01 00:00:00

  • What do we learn from immunomodulation in patients with immune thrombocytopenia?

    abstract::Current therapeutic strategies for autoimmune diseases primarily rely on immunosuppression, but global immune suppression results in an increased risk for severe infection and malignancy. In contrast, immuomodulation is another therapeutic approach employing intrinsic or environmental regulators that exert modulatory ...

    journal_title:Seminars in hematology

    pub_type: 杂志文章

    doi:10.1053/j.seminhematol.2016.04.009

    authors: Kuwana M

    更新日期:2016-04-01 00:00:00